Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab vs placebo and etanercept in pediatric severe chronic plaque psoriasis
jRCT2080223229Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in psoriasis (4 arms), sponsored by Novartis. Primary endpoint: Short-term efficacy at Week 12. Started Jun 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on jRCT2080223229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223229.